U.S. authorities have opened investigations into Chinese state support and pricing practices in the biotech sector, with the International Trade Commission and related agencies examining whether government interventions distorted competition and disadvantaged American firms. BioCentury coverage and ITC notices indicate the probe could set the stage for tariffs or other trade restrictions if harmful subsidies are found. The inquiry targets a range of policies, from direct funding to pricing support and procurement strategies that may affect global supply chains and deal economics. U.S. officials signaled that findings could reshape how Western investors and companies engage with Chinese biotech partners. Life‑science companies and investors are watching closely: potential trade measures would influence licensing, manufacturing, and cross‑border collaborations vital to global drug development pipelines.